60.55
price up icon14.61%   7.72
pre-market  プレマーケット:  59.05   -1.50   -2.48%
loading
前日終値:
$52.83
開ける:
$56.08
24時間の取引高:
1.10M
Relative Volume:
2.43
時価総額:
$1.68B
収益:
$169.47M
当期純損益:
$-84.63M
株価収益率:
-21.48
EPS:
-2.8189
ネットキャッシュフロー:
$-145.42M
1週間 パフォーマンス:
+9.87%
1か月 パフォーマンス:
+25.16%
6か月 パフォーマンス:
+187.10%
1年 パフォーマンス:
+297.05%
1日の値動き範囲:
Value
$54.17
$62.69
1週間の範囲:
Value
$52.68
$62.69
52週間の値動き範囲:
Value
$15.12
$62.69

Anaptysbio Inc Stock (ANAB) Company Profile

Name
名前
Anaptysbio Inc
Name
セクター
Healthcare (1106)
Name
電話
858-362-6295
Name
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
職員
136
Name
Twitter
@anaptysbio
Name
次回の収益日
2024-11-08
Name
最新のSEC提出書
Name
ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ANAB
Anaptysbio Inc
60.55 1.46B 169.47M -84.63M -145.42M -2.8189
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-10-13 開始されました Barclays Overweight
2025-06-04 アップグレード H.C. Wainwright Neutral → Buy
2025-02-04 開始されました Wolfe Research Outperform
2024-12-11 ダウングレード H.C. Wainwright Buy → Neutral
2024-12-02 ダウングレード BTIG Research Buy → Neutral
2024-07-22 開始されました H.C. Wainwright Buy
2024-07-19 アップグレード JP Morgan Neutral → Overweight
2024-04-16 開始されました Leerink Partners Outperform
2024-04-11 開始されました Wells Fargo Overweight
2024-03-12 アップグレード Wedbush Neutral → Outperform
2024-02-26 開始されました BTIG Research Buy
2024-02-21 開始されました Stifel Buy
2024-02-16 開始されました Piper Sandler Overweight
2023-05-22 アップグレード JP Morgan Underweight → Neutral
2023-05-18 開始されました TD Cowen Outperform
2023-01-06 ダウングレード Raymond James Outperform → Mkt Perform
2022-11-01 アップグレード Guggenheim Neutral → Buy
2022-09-19 再開されました H.C. Wainwright Buy
2022-09-13 ダウングレード Truist Buy → Hold
2022-09-01 開始されました Raymond James Outperform
2022-03-22 ダウングレード Guggenheim Buy → Neutral
2021-06-22 開始されました H.C. Wainwright Buy
2021-05-21 開始されました UBS Neutral
2021-03-16 アップグレード Truist Hold → Buy
2021-03-09 ダウングレード Wedbush Outperform → Neutral
2021-03-08 ダウングレード JP Morgan Overweight → Underweight
2021-02-11 アップグレード JP Morgan Underweight → Overweight
2020-10-27 アップグレード Wedbush Neutral → Outperform
2020-10-14 アップグレード Guggenheim Neutral → Buy
2019-11-08 ダウングレード JP Morgan Overweight → Underweight
2019-11-08 ダウングレード Jefferies Buy → Hold
2019-11-08 ダウングレード SunTrust Buy → Hold
2019-11-08 ダウングレード Wedbush Outperform → Neutral
2019-06-21 ダウングレード Credit Suisse Outperform → Neutral
2019-06-21 ダウングレード Stifel Buy → Hold
2018-12-20 開始されました H.C. Wainwright Buy
2018-11-21 開始されました JP Morgan Overweight
2018-07-19 開始されました Credit Suisse Outperform
2018-04-04 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-03-27 繰り返されました Stifel Buy
2018-03-06 繰り返されました Stifel Buy
2018-02-15 繰り返されました SunTrust Buy
2018-01-23 繰り返されました Credit Suisse Outperform
2017-11-15 開始されました SunTrust Buy
2017-11-09 開始されました Jefferies Buy
2017-10-11 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
すべてを表示

Anaptysbio Inc (ANAB) 最新ニュース

pulisher
07:36 AM

Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus

07:36 AM
pulisher
01:10 AM

AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada

01:10 AM
pulisher
Mar 04, 2026

AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada

Mar 04, 2026
pulisher
Mar 04, 2026

Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com

Mar 04, 2026
pulisher
Mar 04, 2026

AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq

Mar 04, 2026
pulisher
Mar 04, 2026

HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus

Mar 04, 2026
pulisher
Mar 03, 2026

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Mil - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio earnings beat by $0.71, revenue topped estimates - Investing.com Canada

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio Q4 Swings to Profit, Revenue Rises - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 71c - StreetInsider

Mar 03, 2026
pulisher
Mar 03, 2026

Anaptysbio 10-K: $234.6M Revenue, $(0.46) EPS - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Planned AnaptysBio (NASDAQ: ANAB) split separates royalties from pipeline - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio, Inc. Announces Spin-off of Biopharma Operations to Form First Tracks Biotherapeutics, Targeting Q2 2026 - Quiver Quantitative

Mar 03, 2026
pulisher
Mar 03, 2026

Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q4 Revenue $108.2M, vs. FactSet Est of $87.0M - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

AnaptysBio (NASDAQ: ANAB) Q4 profit, royalties surge and 2026 spin-off - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Commit To Buy AnaptysBio At $35, Earn 15.9% Annualized Using Options - Nasdaq

Mar 03, 2026
pulisher
Feb 28, 2026

ANAB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026
pulisher
Feb 28, 2026

ANAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

AnaptysBio, Inc. (ANAB) Stock Analysis: A Biotech With 21% Potential Upside - DirectorsTalk Interviews

Feb 27, 2026
pulisher
Feb 25, 2026

FDA accepts Vanda’s imsidolimab application for rare skin disorder - Investing.com

Feb 25, 2026
pulisher
Feb 25, 2026

FDA accepts Vanda’s imsidolimab application for rare skin disorder By Investing.com - Investing.com UK

Feb 25, 2026
pulisher
Feb 25, 2026

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - ChartMill

Feb 25, 2026
pulisher
Feb 24, 2026

AnaptysBio stock hits 52-week high at $57.73 By Investing.com - Investing.com Canada

Feb 24, 2026
pulisher
Feb 24, 2026

AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighTime to Buy? - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

AnaptysBio stock hits 52-week high at $57.73 - Investing.com

Feb 24, 2026
pulisher
Feb 24, 2026

Big Picture: Can AnaptysBio Inc grow without external fundingWeekly Trade Review & Proven Capital Preservation Tips - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 23, 2026

How Anaptysbio Inc. (ANAB) Affects Rotational Strategy Timing - Stock Traders Daily

Feb 23, 2026
pulisher
Feb 21, 2026

Skandinaviska Enskilda Banken AB publ Has $4.45 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat

Feb 21, 2026
pulisher
Feb 20, 2026

AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 19, 2026

AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday - Defense World

Feb 19, 2026
pulisher
Feb 19, 2026

AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP - MarketBeat

Feb 19, 2026
pulisher
Feb 16, 2026

ANAB PE Ratio & Valuation, Is ANAB Overvalued - Intellectia AI

Feb 16, 2026
pulisher
Feb 13, 2026

AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat

Feb 13, 2026
pulisher
Feb 13, 2026

AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors - DirectorsTalk Interviews

Feb 13, 2026
pulisher
Feb 13, 2026

AnaptysBio Insider Sells $540,000 in Stock - National Today

Feb 13, 2026
pulisher
Feb 12, 2026

AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - MarketBeat

Feb 12, 2026

Anaptysbio Inc (ANAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Anaptysbio Inc (ANAB) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
Feb 11 '26
Sale
54.00
10,000
540,000
12,835
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):